Victor E. Reuter

Q: What Schools Are Affiliated With Victor E. Reuter

Victor E. Reuter is affiliated with the following schools: Cornell University, Lund University, University of New Mexico, Okayama University, Tokyo Medical University, Columbia University, Thomas Jefferson University, Karolinska Institute

Victor E. Reuter's AcademicInfluence.com Rankings

Victor E. Reuter

Philosophy

#3694

World Rank

#5917

Historical Rank

Logic

#1336

World Rank

#2059

Historical Rank

philosophy Degrees

Victor E. Reuter

Biology

#4651

World Rank

#6916

Historical Rank

Computational Biology

#64

World Rank

#64

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Why Is Victor E. Reuter Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Victor E. Reuter's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Integrative genomic profiling of human prostate cancer. (2010) (3312)
Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (2458)
The Molecular Taxonomy of Primary Prostate Cancer (2015) (2116)
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. (2016) (1914)
Comprehensive molecular characterization of urothelial bladder carcinoma (2014) (1748)
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer (2017) (1446)
The Heidelberg classification of renal cell tumours (1997) (1125)
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. (2016) (1101)
A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. (2016) (1075)
Clinical-grade computational pathology using weakly supervised deep learning on whole slide images (2019) (1042)
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. (2016) (931)
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. (1999) (763)
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. (2004) (741)
High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. (2001) (726)
Genomic correlates of clinical outcome in advanced prostate cancer (2019) (647)
Surgical management of renal tumors 4 cm. or less in a contemporary cohort. (2000) (644)
DOSE ESCALATION WITH THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY AFFECTS THE OUTCOME IN PROSTATE CANCER (1998) (616)
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. (2004) (590)
Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. (2001) (566)
Aberrant Nuclear Immunoreactivity for TFE3 in Neoplasms With TFE3 Gene Fusions: A Sensitive and Specific Immunohistochemical Assay (2003) (538)
Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. (1993) (536)
Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. (2002) (524)
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (2018) (480)
A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. (2005) (475)
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma (2007) (464)
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. (2016) (459)
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer (2008) (453)
Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. (2002) (452)
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. (2014) (445)
Cystectomy for bladder cancer: a contemporary series. (2001) (441)
Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures (2016) (433)
Prostate-specific membrane antigen is produced in tumor-associated neovasculature. (1999) (418)
Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. (2005) (411)
Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation (2014) (405)
Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (383)
Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. (1999) (379)
Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. (1998) (370)
Xp11 Translocation Renal Cell Carcinoma in Adults: Expanded Clinical, Pathologic, and Genetic Spectrum (2007) (369)
Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade (2019) (364)
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. (2007) (350)
Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. (1992) (345)
Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. (2003) (338)
Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group‐related antigens (1997) (335)
The role of SPINK1 in ETS rearrangement-negative prostate cancers. (2008) (327)
Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores (2015) (322)
Renal oncocytoma: a clinicopathologic study of 70 cases. (1997) (317)
PRCC-TFE3 Renal Carcinomas: Morphologic, Immunohistochemical, Ultrastructural, and Molecular Analysis of an Entity Associated With the t(X;1)(p11.2;q21) (2002) (310)
Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. (2017) (309)
Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. (2001) (303)
Copy number alteration burden predicts prostate cancer relapse (2014) (295)
Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma (2017) (294)
Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network (2013) (294)
Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. (2006) (292)
Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression (1998) (279)
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer (2018) (277)
Renal Carcinomas With the t(6;11)(p21;q12): Clinicopathologic Features and Demonstration of the Specific Alpha-TFEB Gene Fusion by Immunohistochemistry, RT-PCR, and DNA PCR (2005) (270)
Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer (2010) (269)
Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. (2013) (268)
p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns (1994) (268)
TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. (2009) (267)
Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma (2006) (266)
Tumor size is associated with malignant potential in renal cell carcinoma cases. (2009) (265)
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. (2013) (263)
Integrated Molecular Characterization of Testicular Germ Cell Tumors (2018) (261)
Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides (1997) (260)
Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. 1 1 H. Barton Grossman, M.D (2002) (260)
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer (2010) (254)
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. (2007) (253)
Genetic alterations in bladder cancer (1993) (252)
Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens. (2001) (251)
Molecular genetic alterations in superficial and locally advanced human bladder cancer. (1991) (248)
Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. (2004) (246)
Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures (2016) (241)
Urachal Carcinoma: A Clinicopathologic Analysis of 24 Cases With Outcome Correlation (2009) (239)
Protocol for the examination of specimens from patients with carcinoma of the prostate gland. (2009) (235)
Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. (1995) (233)
Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. (1997) (229)
Histopathological, cytogenetic, and molecular characterization of renal cortical tumors. (1991) (229)
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome (2007) (228)
Primary renal synovial sarcoma: molecular and morphologic delineation of an entity previously included among embryonal sarcomas of the kidney. (2000) (225)
Preferential association of human papillomavirus with high-grade histologic variants of penile-invasive squamous cell carcinoma. (1995) (224)
ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology. (2013) (223)
Translocation carcinomas of the kidney after chemotherapy in childhood. (2006) (218)
Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings. (2008) (218)
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. (2013) (210)
An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. (2013) (209)
Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma (1993) (208)
Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome–associated Renal Cancer: Recognition of the Syndrome by Pathologic Features and the Utility of Detecting Aberrant Succination by Immunohistochemistry (2014) (203)
Prognostic significance of location of positive margins in radical prostatectomy specimens. (2007) (200)
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. (1988) (199)
Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy (2014) (198)
Epigenetic expansion of VHL-HIF signal output drives multi-organ metastasis in renal cancer (2012) (198)
Best Practices Recommendations in the Application of Immunohistochemistry in Urologic Pathology: Report From the International Society of Urological Pathology Consensus Conference (2014) (197)
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma (2009) (195)
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas (2010) (195)
Deletion of the p16 and p15 genes in human bladder tumors. (1995) (194)
Renal oncocytosis: a morphologic study of fourteen cases. (1999) (194)
Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume. (2009) (193)
Altered patterns of MDM2 and TP53 expression in human bladder cancer. (1994) (192)
Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. (1994) (189)
Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. (1998) (189)
Typing of prostate tissue by ultrasonic spectrum analysis (1996) (188)
Genomic Characterization of Upper Tract Urothelial Carcinoma. (2015) (183)
Inverse associations between plasma lycopene and other carotenoids and prostate cancer. (2001) (180)
Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging--initial results. (2003) (178)
Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy (2005) (173)
Origins and molecular biology of testicular germ cell tumors (2005) (171)
Xp11 Translocation Renal Cell Carcinoma (RCC): Extended Immunohistochemical Profile Emphasizing Novel RCC Markers (2010) (170)
Cytogenetic analysis of 124 prospectively ascertained male germ cell tumors. (1992) (169)
Comprehensive prospective comparative analysis of outcomes between open and laparoscopic radical prostatectomy conducted in 2003 to 2005. (2008) (169)
Electrical impedance characterization of normal and cancerous human hepatic tissue (2010) (165)
Urothelial Carcinoma of the Renal Pelvis: A Clinicopathologic Study of 130 Cases (2004) (164)
Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation (1998) (161)
Renal Tumors: Diagnostic and Prognostic Biomarkers (2013) (160)
Isochromosome of Chromosome 12: Clinically Useful Marker for Male Germ Cell Tumors (1989) (159)
Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. (1994) (158)
Aberrant expression of cyclin D2 is an early event in human male germ cell tumorigenesis. (1997) (157)
Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel–Lindau gene and hypoxia-inducible factor pathway-related proteins (2011) (156)
Cytogenetic and molecular analysis of human male germ cell tumors: Chromosome 12 abnormalities and gene amplification (1990) (151)
TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers (2016) (151)
Incidence of benign lesions for clinically localized renal masses smaller than 7 cm in radiological diameter: influence of sex. (2006) (148)
Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. (2002) (144)
Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings--initial observations. (2004) (144)
Warty (condylomatous) squamous cell carcinoma of the penis: a report of 11 cases and proposed classification of 'verruciform' penile tumors. (2000) (144)
Long-term outcome among men with conservatively treated localised prostate cancer (2006) (143)
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. (2008) (142)
Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors (2004) (142)
HER‐2 profiling and targeting in prostate carcinoma (2002) (140)
Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer (2015) (140)
Concurrent Angiomyolipoma and Renal Cell Neoplasia: A Study of 36 Cases (2001) (140)
Molecular cytogenetic analysis of i(12p)‐negative human male germ cell tumors (1993) (139)
Clinical and Pathobiological Effects of Neoadjuvant Total Androgen Ablation Therapy on Clinically Localized Prostatic Adenocarcinoma (1994) (139)
A recurring translocation, t(11;22)(p13;q11.2), characterizes intra-abdominal desmoplastic small round-cell tumors. (1993) (139)
A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. (2017) (138)
Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. (1993) (138)
The malignant nature of papillary and cystic neoplasm of the pancreas (1991) (138)
The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy (2004) (137)
Basaloid squamous cell carcinoma: a distinctive human papilloma virus-related penile neoplasm: a report of 20 cases. (1998) (137)
Contemporary approach to the classification of renal epithelial tumors. (2000) (136)
Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer (2016) (135)
Urachal carcinoma: contemporary surgical outcomes. (2007) (135)
Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. (2008) (135)
Cytogenetic and immunohistochemical evidence for the germ cell origin of a subset of acute leukemias associated with mediastinal germ cell tumors. (1990) (135)
Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial. (2019) (134)
Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome. (1996) (134)
Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. (2008) (134)
Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. (2015) (133)
SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. (2010) (131)
Immunophenotype of High-Grade Prostatic Adenocarcinoma and Urothelial Carcinoma (2000) (131)
Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study (2009) (130)
The pathology of renal epithelial neoplasms. (2006) (129)
Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. (2016) (129)
Expanding the Histologic Spectrum of Mucinous Tubular and Spindle Cell Carcinoma of the Kidney (2006) (127)
Management of low grade papillary bladder tumors. (2007) (126)
Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets (2016) (125)
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer (2015) (123)
Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. (1997) (121)
Angiomyolipoma With Epithelial Cysts (AMLEC): A Distinct Cystic Variant of Angiomyolipoma (2006) (120)
The clinical features of anterior prostate cancers (2006) (118)
Leukemic differentiation of a mediastinal germ cell tumor (1989) (118)
Improved prediction of prostate cancer recurrence through systems pathology. (2007) (116)
Chromophobe Renal Cell Carcinoma: A Clinicopathologic Study of 203 Tumors in 200 Patients With Primary Resection at a Single Institution (2011) (116)
Critical function for ADAM9 in mouse prostate cancer. (2005) (116)
Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. (2009) (115)
Impact of a second transurethral resection on the staging of T1 bladder cancer. (2002) (114)
Clinical significance of repeat sextant biopsies in prostate cancer patients. (1997) (113)
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. (2014) (113)
Allelic deletions in the long arm of chromosome 12 identify sites of candidate tumor suppressor genes in male germ cell tumors. (1992) (111)
Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. (2001) (108)
Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. (1995) (108)
A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. (2013) (108)
89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer (2014) (108)
TMPRSS2–ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features (2010) (108)
Whole slide imaging equivalency and efficiency study: experience at a large academic center (2019) (108)
TCEB1-mutated Renal Cell Carcinoma: A Distinct Genomic and Morphologic Subtype (2014) (107)
Interobserver Reproducibility in the Diagnosis of Invasive Micropapillary Carcinoma of the Urinary Tract Among Urologic Pathologists (2010) (107)
ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression (2006) (107)
Mucinous Tubular and Spindle Cell Carcinoma of the Kidney With Sarcomatoid Change (2009) (106)
Cytogenetic analysis of human solid tumors by in situ hybridization with a set of 12 chromosome-specific DNA probes. (1990) (105)
Clinical Relevance of the i(12p) Chromosome in Germ cell Tumors (1994) (103)
Erratum : The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (Cell Reports (2018) 23(1) (313–326.e5) (S2211124718304364) (10.1016/j.celrep.2018.03.075)) (2018) (103)
Characterization of KRAS rearrangements in metastatic prostate cancer. (2011) (102)
New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia (2021) (102)
The pathology of bladder cancer. (2006) (101)
Best Practices Recommendations in the Application of Immunohistochemistry in the Kidney Tumors: Report From the International Society of Urologic Pathology Consensus Conference (2014) (101)
Molecular Genetic Alterations of Chromosome 17 and p53 Nuclear Overexpression in Human Bladder Cancer (1993) (101)
Normal central zone of the prostate and central zone involvement by prostate cancer: clinical and MR imaging implications. (2012) (100)
Characteristic promoter hypermethylation signatures in male germ cell tumors (2002) (99)
Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. (1998) (99)
Molecular genetics of testicular germ cell tumors. (2012) (99)
Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma (2016) (98)
Abnormalities at chromosome region 3p12-14 characterize clear cell renal carcinoma. (1987) (98)
Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. (2008) (98)
Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia (2021) (98)
Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. (2008) (98)
Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. (2001) (97)
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. (2021) (96)
Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. (2007) (96)
Epithelioid angiomyolipoma of the kidney: pathological features and clinical outcome in a series of consecutively resected tumors (2013) (96)
Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen. (1989) (96)
Glutathione S-transferase PI (GST-pi) class expression by immunohistochemistry in benign and malignant prostate tissue. (1997) (96)
Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. (1994) (94)
Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. (2001) (93)
TFEB-amplified Renal Cell Carcinomas: An Aggressive Molecular Subset Demonstrating Variable Melanocytic Marker Expression and Morphologic Heterogeneity (2016) (92)
Nested Variant of Urothelial Carcinoma: A Clinicopathologic and Immunohistochemical Study of 12 Cases (2003) (92)
Grading of Invasive Cribriform Carcinoma on Prostate Needle Biopsy: An Interobserver Study among Experts in Genitourinary Pathology (2008) (90)
Allelic loss and somatic differentiation in human male germ cell tumors. (1994) (90)
Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma (2012) (89)
Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation. (1990) (89)
Blood group-related antigens in human urothelium: enhanced expression of precursor, LeX, and LeY determinants in urothelial carcinoma. (1988) (88)
t(6;11) Renal Cell Carcinoma (RCC): Expanded Immunohistochemical Profile Emphasizing Novel RCC Markers and Report of 10 New Genetically Confirmed Cases (2014) (88)
Association of Cysteine-Rich Secretory Protein 3 and β-Microseminoprotein with Outcome after Radical Prostatectomy (2007) (88)
Carbonic Anhydrase IX Expression in Clear Cell Renal Cell Carcinoma: An Immunohistochemical Study Comparing 2 Antibodies (2008) (87)
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. (2018) (86)
Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study. (2012) (86)
Anterior-predominant Prostatic Tumors: Zone of Origin and Pathologic Outcomes at Radical Prostatectomy (2008) (86)
Cancer-Testis Antigens: Expression and Correlation with Survival in Human Urothelial Carcinoma (2006) (86)
Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue (1997) (85)
Re‐evaluation of 33 ‘unclassified’ eosinophilic renal cell carcinomas in young patients (2018) (84)
β4 Integrin signaling induces expansion of prostate tumor progenitors. (2013) (84)
RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH (2017) (84)
Treatment outcome for metastatic papillary renal cell carcinoma patients (2006) (83)
Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. (2017) (83)
Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase–deficient Renal Cell Carcinoma (2018) (83)
Protocol for the examination of specimens from patients with carcinoma of the penis. (2010) (82)
Chromosome 3 allelic losses and microsatellite alterations in transitional cell carcinoma of the urinary bladder. (1996) (81)
Sarcomatoid-variant Renal Cell Carcinoma: Treatment Outcome and Survival in Advanced Disease (2011) (81)
Validation of a digital pathology system including remote review during the COVID-19 pandemic (2020) (81)
Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. (2008) (81)
Somatic mutation of fibroblast growth factor receptor‐3 (FGFR3) defines a distinct morphological subtype of high‐grade urothelial carcinoma (2011) (81)
The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. (1997) (80)
Collecting duct carcinoma versus renal medullary carcinoma: an appeal for nosologic and biological clarity. (2014) (80)
A Survey of DICER1 Hotspot Mutations in Ovarian and Testicular Sex Cord-Stromal Tumors (2015) (80)
Testicular Seminoma: A Clinicopathologic and Immunohistochemical Study of 105 Cases with Special Reference to Seminomas with Atypical Features (2002) (80)
Presence of Somatic Mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in Cisplatin-Resistant Germ Cell Tumors (2014) (80)
Bladder biopsy interpretation (2004) (78)
NUTM1 Gene Fusions Characterize a Subset of Undifferentiated Soft Tissue and Visceral Tumors (2018) (78)
Peanut lectin-binding sites in polyps of the colon and rectum. Adenomas, hyperplastic polyps, and adenomas with in situ carcinoma. (1983) (77)
Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm (2019) (77)
Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas (2009) (77)
Duplication of the fusion of TMPRSS 2 to ERG sequences identifies fatal human prostate cancer (2009) (76)
Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma (2006) (75)
Histopathologic effects of three-dimensional conformal external beam radiation therapy on benign and malignant prostate tissues. (1999) (75)
Nomogram incorporating PSA level to predict cancer‐specific survival for men with clinically localized prostate cancer managed without curative intent (2008) (75)
Immunoexpression Status and Prognostic Value of mTOR and Hypoxia-Induced Pathway Members in Primary and Metastatic Clear Cell Renal Cell Carcinomas (2011) (75)
Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. (2003) (74)
Allelic deletions in renal tumors: histopathological correlations. (1993) (74)
Prostate-specific membrane antigen expression in regeneration and repair (2008) (73)
Hyperpolarized MRI of Human Prostate Cancer Reveals Increased Lactate with Tumor Grade Driven by Monocarboxylate Transporter 1. (2020) (73)
Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression. (2006) (72)
Oncocytic adrenal cortical adenoma. (1991) (72)
Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. (2009) (72)
Bilateral non-familial renal cell carcinoma (1998) (71)
Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement (2009) (69)
Immunoanatomic distribution of blood group antigens in the human urinary tract. Influence of secretor status. (1986) (69)
Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma. (2007) (69)
Mechanisms of prostatic stromal invasion in patients with bladder cancer: clinical significance. (2001) (68)
Diagnostic significance of mitochondria in four types of renal epithelial neoplasms: an ultrastructural study of 60 tumors. (1997) (68)
Bladder neck involvement in pathological stage pT4 radical prostatectomy specimens is not an independent prognostic factor. (2002) (67)
Comparative genomic hybridization for genetic analysis of renal oncocytomas (1996) (67)
Differential Diagnosis of Renal Tumors With Papillary Architecture (2011) (66)
Quality improvement in laparoscopic radical prostatectomy for pT2 prostate cancer: impact of video documentation review on positive surgical margin. (2005) (65)
Comparison of Morphologic Features and Outcome of Resected Recurrent and Nonrecurrent Squamous Cell Carcinoma of the Penis: A Study of 81 Cases (2009) (65)
Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. (1998) (65)
Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. (1995) (64)
Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. (2019) (64)
Role of Immunohistochemistry in the Evaluation of Needle Core Biopsies in Adult Renal Cortical Tumors: An Ex Vivo Study (2011) (64)
Gene expression-based classification of nonseminomatous male germ cell tumors (2005) (63)
Oncologic outcome after laparoscopic radical prostatectomy: 10 years of experience. (2009) (63)
Pathology and staging of urothelial tumors of the kidney and ureter. (1993) (63)
Anatomy of the prostate revisited: implications for prostate biopsy and zonal origins of prostate cancer (2012) (63)
Long-term follow-up of bilateral sporadic renal tumors. (2003) (63)
Ultrasonic spectral-parameter imaging of the prostate (1997) (62)
Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis (2017) (62)
Recommendations for the reporting of resected prostate carcinomas. Association of Directors of Anatomic and Surgical Pathology. (1996) (62)
Clinical outcome of patients with T1 micropapillary urothelial carcinoma of the bladder. (2013) (62)
Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein (2013) (62)
Clinical stage T1c prostate cancer: evaluation with endorectal MR imaging and MR spectroscopic imaging. (2009) (62)
Interobserver and intraobserver reproducibility in digital and routine microscopic assessment of prostate needle biopsies. (2011) (61)
Susceptibility Loci Associated with Prostate Cancer Progression and Mortality (2010) (61)
Telomerase activity in germ cell cancers and mature teratomas. (1999) (60)
Copy number and gene expression differences between African American and Caucasian American prostate cancer (2010) (60)
A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. (2009) (59)
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma. (2016) (59)
Sex cord-stromal tumors of the testis with entrapped germ cells: a lesion mimicking unclassified mixed germ cell sex cord-stromal tumors. (2000) (59)
Abnormalities of 2q: A common genetic link between rhabdomyosarcoma and hepatoblastoma? (1991) (59)
Can p53 help select patients with invasive bladder cancer for bladder preservation? (1999) (59)
In vivo differentiation and genomic evolution in adult male germ cell tumors (2008) (59)
Differential diagnosis of renal tumours with clear cell histology. (2010) (58)
Small cell neuroendocrine carcinoma of the urinary bladder. A clinicopathologic study with emphasis on cytologic features. (1997) (58)
Sarcomatoid lesions of the urogenital tract. (1993) (57)
Is intraoperative frozen section analysis an efficient way to reduce positive surgical margins? (2005) (56)
Genetic analysis as an aid in diagnosis for patients with midline carcinomas of uncertain histologies. (1991) (56)
Small cell neuroendocrine carcinoma with skeletal muscle differentiation: report of three cases. (2000) (56)
Detection and analysis of origin of i(12p), a diagnostic marker of human male germ cell tumors, by fluorescence in situ hybridization (1991) (56)
Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma (2005) (54)
Implementation of Digital Pathology Offers Clinical and Operational Increase in Efficiency and Cost Savings. (2019) (54)
Risk-adjusted analysis of positive surgical margins following laparoscopic and retropubic radical prostatectomy. (2007) (54)
Frequent allelic deletions and loss of expression characterize the DCC gene in male germ cell tumors. (1994) (53)
Salvage chemotherapy for patients with advanced pure seminoma. (2002) (53)
Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. (1992) (53)
Cancer‐specific survival and predictors of prostate‐specific antigen recurrence and survival in patients with seminal vesicle invasion after radical prostatectomy (2006) (53)
Carcinosarcoma of the Prostate (1993) (52)
Genomic and expression analysis of the 12p11-p12 amplicon using EST arrays identifies two novel amplified and overexpressed genes. (2002) (52)
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumors. (1988) (52)
Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney. (2002) (52)
Protocol for the examination of specimens from patients with invasive carcinoma of renal tubular origin. (2010) (52)
The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer. (2000) (52)
Morphologic Features of Uterine Leiomyomas Associated With Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome: A Case Report (2011) (52)
Hypoxia-inducible factor (HIF) 1{alpha} and 2{alpha} levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC) (2008) (52)
Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection (2017) (51)
Chordomas with malignant spindle cell components. A DNA flow cytometric and immunohistochemical study with histogenetic implications. (1990) (51)
Malignant epithelial tumors (2004) (51)
Ultrasonic spectral‐parameter imaging of the prostate (1997) (50)
Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC): A Rapid Autopsy Report of Metastatic Renal Cell Carcinoma (2014) (50)
P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. (1994) (50)
Glomus Tumor of the Kidney: A Report of 3 Cases Involving Renal Parenchyma and Review of the Literature (2007) (50)
Small cell neuroendocrine carcinoma of the urinary bladder (1997) (48)
Blood group-related antigens in human kidney: modulation of Lewis determinants in renal cell carcinoma. (1989) (48)
Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading (2007) (47)
Impact of a multidisciplinary continuous quality improvement program on the positive surgical margin rate after laparoscopic radical prostatectomy. (2006) (47)
Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder (2007) (47)
PRKC-ζ Expression Promotes the Aggressive Phenotype of Human Prostate Cancer Cells and Is a Novel Target for Therapeutic Intervention. (2010) (47)
Protective effects of plasma carotenoids on the risk of bladder cancer. (2006) (47)
Detection of preferential NRAS mutations in human male germ cell tumors by the polymerase chain reaction (1990) (47)
Clinical relevance of the i(12p) marker chromosome in germ cell tumors. (1994) (47)
Alterations of tumor suppressor genes in bladder cancer. (1997) (47)
Immunopathology of adrenal and renal cortical tumors. Coordinated change in antigen expression is associated with neoplastic conversion in the adrenal cortex. (1990) (46)
Overexpression of the retinoic acid receptor gamma directly induces terminal differentiation of human embryonal carcinoma cells. (1995) (46)
Urothelial carcinoma with prominent squamous differentiation in the setting of neurogenic bladder: role of human papillomavirus infection (2012) (46)
Hypoxia‐inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications (2011) (45)
Clinical outcomes of local and metastatic testicular sex cord-stromal tumors. (2013) (45)
Associations between Variants of the 8q24 Chromosome and Nine Smoking-Related Cancer Sites (2008) (45)
Renal vein or inferior vena caval extension in patients with renal cortical tumors: impact of tumor histology. (2004) (45)
JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management (2019) (44)
Bladder. Risk and prognostic factors--a pathologist's perspective. (1999) (44)
Replication error-type genetic instability at 1q42-43 in human male germ cell tumors. (1994) (44)
Renal Medullary Carcinoma: Establishing Standards in Practice. (2017) (44)
Single nucleotide polymorphisms of 8 inflammation‐related genes and their associations with smoking‐related cancers (2010) (43)
Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. (2018) (43)
t(12;22)(q13;q13) and trisomy 8 are nonrandom aberrations in clear-cell sarcoma. (1992) (42)
Recommendations for the reporting of resected prostate carcinomas (1997) (42)
DNA, RNA and immunohistochemical characterization of the HER-2/neu oncogene in transitional cell carcinoma of the bladder. (1991) (42)
Resection of Primary Mediastinal Non-Seminomatous Germ Cell Tumors: A 28-Year Experience at Memorial Sloan-Kettering Cancer Center (2011) (42)
p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer (2009) (42)
Leiomyoma With Bizarre Nuclei: A Morphological, Immunohistochemical and Molecular Analysis of 31 Cases (2017) (41)
Prostate Cancer Topography and Patterns of Lymph Node Metastasis (2010) (41)
Associations between NBS1 polymorphisms, haplotypes and smoking-related cancers. (2010) (41)
Long-Term Outcomes of Active Surveillance for Prostate Cancer - The Memorial Sloan Kettering Cancer Center Experience. (2019) (41)
A Nomogram For Predicting a Positive Repeat Prostate Biopsy in Patients With a Previous Negative Biopsy Session (2003) (40)
Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI. (2010) (40)
Three-dimensional ultrasound analyses of the prostate. (2000) (40)
Initial Results with 11C-Acetate Positron Emission Tomography/Computed Tomography (PET/CT) in the Staging of Urinary Bladder Cancer (2012) (40)
Up-Regulation of Retinoic Acid Receptor β Expression in Renal Cancers in Vivo Correlates with Response to 13-cis-Retinoic Acid and Interferon-α-2a (1999) (40)
Cytotoxic Treatment of Aggressive Prostate Tumors with or without Neuroendocrine Elements (2002) (40)
Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer (1996) (39)
The "WHO/ISUP Consensus Classification of Urothelial (Transitional Cell) Neoplasms": continued discussion. (1999) (39)
Glutathione S-transferase P1 Ile105Val polymorphism, cigarette smoking and prostate cancer. (2004) (39)
Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists (2015) (39)
P53 nuclear overexpression and disease progression in ta-bladder carcinoma. (1993) (39)
Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer. (1993) (38)
Analysis of p21WAF1/CIP1 in primary bladder tumors. (1998) (38)
Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. (2017) (38)
Benign mimics of prostatic adenocarcinoma on needle biopsy. (1997) (38)
Prediction of Prostate Cancer Recurrence Using Magnetic Resonance Imaging and Molecular Profiles (2009) (38)
Renal tumors exhibiting granular cytoplasm. (1999) (37)
Melanoma of the larynx (1986) (37)
Intrarenal Schwannoma: A Report of Four Cases Including Three Cellular Variants (2000) (37)
Analysis of chromosome 12 aneuploidy in interphase cells from human male germ cell tumors by fluorescence in situ hybridization (1992) (37)
Comedonecrosis Revisited: Strong Association With Intraductal Carcinoma of the Prostate (2018) (36)
Pathological Stage T3a Significantly Increases Disease Recurrence across All Tumor Sizes in Renal Cell Carcinoma. (2014) (36)
Expression of prostate-specific membrane antigen in renal cortical tumors (2008) (36)
The association between statin medication and progression after surgery for localized renal cell carcinoma. (2012) (35)
Prostate cancer diagnosed after repeat biopsies have a favorable pathological outcome but similar recurrence rate. (2006) (35)
Prostate-specific membrane antigen: present and future applications. (2000) (35)
Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer. (2002) (35)
Validating Whole Slide Imaging Systems for Diagnostic Purposes in Pathology: Guideline Update From the College of American Pathologists in Collaboration With the American Society for Clinical Pathology and the Association for Pathology Informatics. (2021) (35)
Anatomy of the Anterior Prostate and Extraprostatic Space: A Contemporary Surgical Pathology Analysis (2007) (35)
Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. (1997) (35)
Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group. (2008) (34)
Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. (2016) (34)
Prognostic impact of subclassification of radical prostatectomy positive margins by linear extent and Gleason grade. (2013) (34)
Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases (2019) (33)
Renal cell carcinoma genetic analysis by comparative genomic hybridization and restriction fragment length polymorphism analysis. (1996) (33)
Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. (2016) (32)
Distinct Genomic Copy Number Alterations Distinguish Mucinous Tubular and Spindle Cell Carcinoma of the Kidney From Papillary Renal Cell Carcinoma With Overlapping Histologic Features (2018) (32)
Pilot study of salvage laparoscopic prostatectomy for the treatment of recurrent prostate cancer (2011) (32)
Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors. (2003) (32)
What is the prognostic significance of lymphovascular invasion in radical prostatectomy specimens? (2007) (32)
Prospective evaluation of plasma kinetic bipolar resection of bladder cancer: comparison to monopolar resection and pathologic findings (2014) (32)
Do Prostatic Transition Zone Tumors Have a Distinct Morphology? (2008) (31)
Clinical Usefulness of Total Length of Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer (2019) (31)
Primary squamous cell carcinoma of the prostate after radiation seed implantation for adenocarcinoma. (1995) (31)
Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder (2019) (31)
PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology (2019) (31)
Correlation of MR imaging and MR spectroscopic imaging findings with Ki-67, phospho-Akt, and androgen receptor expression in prostate cancer. (2009) (31)
Genetic alterations in tp53 in recurrent urothelial cancer: a longitudinal study. (2001) (31)
Genomic deregulation during metastasis of renal cell carcinoma implements a myofibroblast-like program of gene expression. (2010) (31)
Deletion mapping identifies loss of heterozygosity at 5p15.1-15.2, 5q11 and 5q34-35 in human male germ cell tumors. (1996) (30)
Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma (BHP RCC) (2020) (30)
FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas (1998) (29)
Ewing's sarcoma/primitive neuroectodermal tumor of the ureter: a case report and review of the literature. (2000) (29)
Localized herpes simplex lymphadenitis. (1986) (29)
Chromosome 12 abnormalities in malignant ovarian germ cell tumors. (1995) (29)
Cytologic features of the nested variant of urothelial carcinoma (2002) (29)
A pilot study of immunization with interleukin-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma. (1992) (28)
Experience with neoadjuvant diethylstilboestrol and radical prostatectomy in patients with locally advanced prostate cancer. (1994) (28)
Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. (2017) (28)
Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center. (2020) (28)
Pathology of bladder cancer: assessment of prognostic variables and response to therapy. (1990) (28)
Up-regulation of retinoic acid receptor beta expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-alpha-2a. (1999) (28)
Urothelial Carcinoma Involving the Gynecologic Tract: A Morphologic and Immunohistochemical Study of 6 Cases (2012) (28)
TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49. (1995) (27)
Estrogen and progesterone-receptor-positive stroma as a non-tumorous proliferation in kidneys: a possible metaplastic response to obstruction (2008) (27)
Lymphovascular invasion as an independent predictor of recurrence and survival in node-negative bladder cancer remains to be proven. (2005) (27)
Updated protocol for the examination of specimens from patients with carcinoma of the urinary bladder, ureter, and renal pelvis. (2003) (27)
TFEB Expression Profiling in Renal Cell Carcinomas (2019) (27)
Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma (2019) (27)
Integrating digital pathology into clinical practice (2021) (27)
Autopsy Findings in 14 Patients With Penile Squamous Cell Carcinoma (2011) (27)
Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues (2000) (27)
Tubulocystic renal cell carcinoma: a distinct clinicopathologic entity with a characteristic genomic profile (2019) (26)
Renal Myxoma: A Report of Two Cases and Review of the Literature (1994) (26)
Isochromosome of the short arm of chromosome 12: clinically useful markers for male germ cell tumors. (1989) (26)
Genetic alterations associated with bladder cancer. (1994) (26)
Prostatic transition zone directed needle biopsies uncommonly sample clinically relevant transition zone tumors. (2009) (26)
Novel MEIS1-NCOA2 Gene Fusions Define a Distinct Primitive Spindle Cell Sarcoma of the Kidney (2018) (26)
Prognostic impact of muscular venous branch invasion in localized renal cell carcinoma cases. (2011) (25)
Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series. (2019) (25)
Aminopeptidase A expression and enzymatic activity in primary human renal cancers. (1998) (25)
VSTM2A Overexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney (2018) (25)
An improved prognostic model for stage T1a and T1b prostate cancer by assessments of cancer extent (2011) (25)
Blood group-related antigens in human germ cell tumors. (1988) (24)
Evaluation of lymph node counts in primary retroperitoneal lymph node dissection (2010) (24)
Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-fetoprotein, and human chorionic gonadotrophin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor. (2003) (23)
INTRATUMORAL HETEROGENEITY OF ERBB2 AMPLIFICATION AND HER2 EXPRESSION IN MICROPAPILLARY UROTHELIAL CARCINOMA: MP48‐03 (2017) (23)
ID gene expression varies with lineage during differentiation of pluripotential male germ cell tumor cell lines (2001) (23)
Follicular neoplasms of the thyroid in men older than 50 years of age. A DNA flow cytometric study. (1990) (23)
Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate (2019) (23)
Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis (2006) (23)
Non‐urothelial carcinomas of the bladder (2019) (23)
Cigarette smoking and chromosome 9 alterations in bladder cancer. (1997) (22)
Decreased retinoid X receptor-alpha protein expression in basal cells occurs in the early stage of human prostate cancer development. (2004) (22)
Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy. (2000) (22)
Biological markers of prognosis in transitional cell carcinoma of the bladder: current concepts. (1993) (22)
The timing and nature of neovascularization of jejunal free flaps: an experimental study in a large animal model. (1999) (22)
Malignant epithelial tumours (2006) (22)
The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. (2020) (22)
Tissue-Based Research in Kidney Cancer: Current Challenges and Future Directions (2008) (22)
Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. (2020) (21)
Primary retroperitoneal lymph node dissection in low-stage testicular germ cell tumors: a detailed pathologic study with clinical outcome analysis with special emphasis on patients who did not receive adjuvant therapy. (2013) (21)
The diagnostic accuracy of percutaneous renal needle core biopsy and its potential impact on the clinical management of renal cortical neoplasms. (2014) (21)
Challenges in Pathologic Staging of Renal Cell Carcinoma: A Study of Interobserver Variability Among Urologic Pathologists (2018) (21)
Comparison of models to predict clinical failure after radical prostatectomy (2009) (21)
Tumor suppressor gene alterations in bladder carcinoma. Translational correlates to clinical practice. (1995) (21)
Urothelial neoplasms in pediatric and young adult patients: A large single-center series. (2017) (20)
Expression of androgen receptor and its phosphorylated forms in breast cancer progression (2013) (20)
Regarding the focal treatment of prostate cancer: inference of the Gleason grade from magnetic resonance spectroscopic imaging. (2009) (19)
Invited Review : The Origin of Mediastinal Germ Cell Tumors in Men (1994) (19)
TMPRSS2–ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry (2013) (19)
The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia (2021) (19)
Clinical Usefulness of Prostate and Tumor Volume Related Parameters following Radical Prostatectomy for Localized Prostate Cancer (2019) (19)
Chromosomal abnormalities in choriocarcinomas of the female. (1995) (18)
Expression of blood group antigens in bladder cancer: current concepts. (1992) (18)
Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. (2019) (18)
Nodal counts during pelvic lymph node dissection for prostate cancer: an objective indicator of quality under the influence of very subjective factors (2012) (18)
Molecularly confirmed primary malignant rhabdoid tumor of the urinary bladder: implications of accurate diagnosis. (2012) (18)
Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures (2016) (18)
M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) and bladder preservation. (1990) (17)
Blood group antigens in normal and neoplastic urothelium (1992) (17)
Body mass index is associated with higher lymph node counts during retroperitoneal lymph node dissection. (2012) (17)
Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression (2020) (17)
Flow cytometry and cytology as response indicators to M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). (1988) (17)
Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas. (2012) (17)
Susceptibility loci associated with prostate cancer progression and mortality. (2010) (17)
Integrated digital pathology at scale: A solution for clinical diagnostics and cancer research at a large academic medical center (2021) (17)
An exploratory study of endorectal magnetic resonance imaging and spectroscopy of the prostate as preoperative predictive biomarkers of biochemical relapse after radical prostatectomy. (2010) (16)
Contemporary lymph node counts during primary retroperitoneal lymph node dissection. (2011) (16)
Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach (2015) (16)
Identification of Prognostic Pathologic Parameters in Squamous Cell Carcinoma of the Penis: Significance and Difficulties (2005) (16)
Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer (2010) (16)
Characterization of prostate cancer with MR spectroscopic imaging and diffusion-weighted imaging at 3 Tesla. (2019) (16)
Sternberg's diagnostic surgical pathology: Sixth edition (2015) (16)
Cooperative Effects of p 53 and pRB Alterations in Primary Superficial Bladder Tumors ' (2006) (16)
Risk and Prognostic Factors- a Pathologist's Perspective (1999) (16)
Impact of recurrent copy number alterations and cancer gene mutations on the predictive accuracy of prognostic models in clear cell renal cell carcinoma. (2014) (16)
A case of incidental adrenocortical oncocytoma (2006) (15)
Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. (2019) (15)
EWSR1-PATZ1 fusion renal cell carcinoma: a recurrent gene fusion characterizing thyroid-like follicular renal cell carcinoma (2021) (15)
The landscape of T cell infiltration in human cancer and its association with antigen presenting gene expression (2015) (15)
Influence of Histologic Criteria and Confounding Factors in Staging Equivocal Cases for Microscopic Perivesical Tissue Invasion (pT3a): An Interobserver Study Among Genitourinary Pathologists (2014) (15)
Microsatellite instability in prostate cancer and response to immune checkpoint blockade. (2018) (14)
Impact of socioeconomic factors on prostate cancer outcomes in black patients treated with surgery. (2008) (14)
Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer. (1992) (14)
Expression of the retinoblastoma gene product in renal tumors. (1996) (14)
Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial (2020) (14)
Integrative Clinical Genomics of Advanced Prostate Cancer Graphical (2015) (14)
Progression of T1 bladder tumors (1999) (14)
Evaluation of new resectoscope loop for transurethral resection of bladder tumors. (1998) (14)
Biopsy Interpretation of the Bladder (2016) (13)
Predictors for Post-treatment Biopsy Outcomes after Prostate Stereotactic Body Radiotherapy. (2021) (13)
A symposium on controversies in the pathology of transitional cell carcinomas of the urinary bladder, Part II. (1997) (13)
Over-expression of transforming growth factor alpha antagonizes the anti-tumorigenic but not the differentiation actions of retinoic acid in a human teratocarcinoma cell. (1993) (13)
Loss of heterozygosity and decreased expression of NME genes correlate with teratomatous differentiation in human male germ cell tumors. (1994) (13)
Dataset for the reporting of urinary tract carcinoma—biopsy and transurethral resection specimen: recommendations from the International Collaboration on Cancer Reporting (ICCR) (2019) (13)
The use of urine-based biomarkers in bladder cancer. (2006) (13)
The pre and post chemotherapy pathologic spectrum of germ cell tumors. (2002) (12)
Subtyping of renal cortical neoplasms in fine needle aspiration biopsies using a decision tree based on genomic alterations detected by fluorescence in situ hybridization (2014) (12)
Workgroup 3: Current prognostic factors and their relevance to staging (1996) (12)
CD38 in Advanced Prostate Cancers (2021) (12)
Can transrectal needle biopsy be optimised to detect nearly all prostate cancer with a volume of ≥0.5 mL? A three‐dimensional analysis (2013) (12)
PTEN loss with ERG-Negative Status is Associated with Lethal Disease after Radical Prostatectomy. (2020) (11)
Adverse Histology, Homozygous Loss of CDKN2A/B, and Complex Genomic Alterations in Locally Advanced / Metastatic Renal Mucinous Tubular and Spindle Cell Carcinoma (2020) (11)
Long-Term Implications of a Positive Posttreatment Biopsy in Patients Treated with External Beam Radiotherapy for Clinically Localized Prostate Cancer (2019) (11)
Neoadjuvant chemotherapy for bladder cancer: the MSKCC experience. (1990) (11)
(Re) Defining the High-Power Field for Digital Pathology (2020) (11)
Cytogenetic analysis of a juvenile granulosa cell tumor. (1992) (11)
Dataset for the reporting of carcinoma of the bladder—cystectomy, cystoprostatectomy and diverticulectomy specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR) (2020) (11)
Longitudinal follow‐up and performance validation of an mRNA‐based urine test (Xpert® Bladder Cancer Monitor ) for surveillance in patients with non‐muscle‐invasive bladder cancer (2021) (11)
Bladder cancer in cystoscopically normal‐appearing mucosa: a case of mistaken identity? (2010) (11)
L-MYC allelotype in renal cell carcinoma. (1996) (10)
Intracardiac teratoma 15 years after treatment of a nonseminomatous germ cell tumor. (1993) (10)
SIU–ICUD on bladder cancer: pathology (2018) (10)
Association of genomic alterations with cisplatin resistance (cisR) in advanced germ cell tumors (aGCT) (2015) (10)
Adult prostatic sarcoma (2004) (10)
Ultrasonic tissue typing of prostate tissue (1994) (10)
TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma (2021) (10)
Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. (2020) (10)
Fine needle aspiration of renal cortical lesions in adults (2009) (10)
Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical cystectomy following systemic chemotherapy (2011) (10)
Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma (2021) (9)
Measurements of cancer extent in a conservatively treated prostate cancer biopsy cohort (2010) (9)
Digital Pathology Operations at an NYC Tertiary Cancer Center During the First 4 Months of COVID-19 Pandemic Response (2021) (9)
Increased expression of androgen receptor (AR) and enzymes involved in androgen synthesis in metastatic prostate cancer: Targets for novel personalized therapies. (2009) (8)
Outcomes After Multidisciplinary Management of Primary Mediastinal Germ Cell Tumors (2020) (8)
A symposium on controversies in the pathology of transitional cell carcinomas of the urinary bladder. Part I. (1996) (8)
Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer (2020) (8)
3-D tissue typing of prostate tissue based on spectral parameters (1995) (8)
Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures (2017) (8)
Bladder cancer: advances in biology and treatment. (1994) (7)
Papillary Renal Cell Carcinoma: A Single Institutional Study of 199 Cases Addressing Classification, Clinicopathologic and Molecular Features, and Treatment Outcome (2021) (7)
Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT). (2018) (7)
Intraoperative touch‐imprint cytology of germ cell neoplasms (1996) (7)
Inverted urothelial papilloma and urothelial carcinoma with inverted growth are histologically and molecularly distinct entities (2020) (7)
Cell surface differentiation antigens of normal urothelium and bladder tumors. (1992) (7)
90: Incidence of Benign Lesions for Clinically Localized Renal Masses < 7cm in Radiologic Diameter: Influence of Gender (2006) (7)
2-D images for biopsy guidance and 3-D images for treatment planning and monitoring of prostate cancer based upon spectrum analysis and neural-network classification (1999) (7)
Secondary Renal Neoplasia Following Chemotherapy or Radiation in Pediatric Patients. (2020) (6)
Granular Cell Tumor of the Bladder: A Report of Six Cases. (2018) (6)
The value of gamma camera and computed tomography data set coregistration to assess Lewis Y antigen targeting in small cell lung cancer by (111)Indium-labeled humanized monoclonal antibody 3S193. (2008) (6)
Improved prostate biopsy guidance using ultrasonic tissue-typing images (1996) (6)
Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer (2017) (6)
The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer (2010) (6)
Perirenal lipoma versus renal cell carcinoma. (1991) (6)
RISK-ADJUSTED ANALYSIS OF POSITIVE SURGICAL MARGINS FOLLOWING LAPAROSCOPIC AND RETROPUBIC RADICAL PROSTATECTOMY (2006) (5)
Antigen expression in renal cell carcinoma. Correlation with histological grade, pathological stage and development of distant metastasis. (1990) (5)
In Organ-confined Prostate Cancer, Tumor Quantitation Not Found to Aid in Prediction of Biochemical Recurrence (2019) (5)
2- and 3-D differentiation of cancerous from benign prostate tissue for diagnosis, monitoring, and planning based on spectrum analysis (1997) (5)
Association of mutations in chromatin modifiers with poor survival in clear cell renal cell carcinoma: Analysis of the Cancer Genome Atlas Project. (2013) (5)
Alterations in genes regulating cell cycle and apoptosis in high-grade urothelial carcinoma. (2011) (5)
Molecular classification of sunitinib response in metastatic renal cell carcinoma (mRCC) patients by gene expression profiling. (2011) (5)
Flow cytometric analysis of primary adenocarcinoma of the bladder. (1987) (5)
ANTIBODIES TO THE INTERNAL AND EXTERNAL DOMAINS OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) REACT WITH TUMOR-ASSOCIATED NEOVASCULATURE (1999) (5)
Four Cycles of Etoposide plus Cisplatin for Patients with Good‐Risk Advanced Germ Cell Tumors (2021) (5)
Multicenter sequential phase II study of flavopiridol plus oxaliplatin (Alvocidib) with or without 5-FU and leucovorin (LV) for patients (pts) with refractory germ cell tumors (GCT) including late relapse (LR). (2014) (4)
RAS/MAPK Pathway Driver Alterations Are Significantly Associated with Oncogenic KIT Mutations in Germ-cell Tumors. (2020) (4)
Interferon-alpha resistance associated genes in renal cell carcinoma identified by expression profiling. (2007) (4)
Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy? (2018) (4)
Protocol for the examination of specimens from patients with carcinoma of the urethra. (2010) (4)
THE 2017 AMERICAN JOINT COMMITTEE ON CANCER EIGHTH EDITION CANCER STAGING MANUAL: CHANGES IN STAGING GUIDELINES FOR CANCERS OF THE KIDNEY, RENAL PELVIS AND URETER, BLADDER, AND URETHRA: MP86‐17 (2017) (4)
Reply re: Murali Varma, Brett Delahunt, Theodorus van der Kwast. Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.05.001: Two Decades of World Health Organisation/International Society of U (2019) (4)
Etoposide and cisplatin (EP) for metastatic good-risk germ cell tumors (GCTs): The Memorial Sloan-Kettering Cancer Center (MSKCC) experience in 944 patients (pts). (2018) (4)
Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma. (2014) (4)
The Quarterly Case: Renal Tumor in a 62-Year-Old Male (1988) (4)
Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas (2021) (4)
Case report 576 (2004) (4)
Pegylated interferon alpha-2B (PEG-Intron) for metastatic renal cell cancer (mRCC): Results of a phase II clinical trial and biologic correlates of response. (2006) (4)
Outcome prediction in adult male germ cell tumor patients through expression profiling (2008) (4)
Analysis of chromosome 12 abnormalities in male germ cell cancers. (1991) (3)
Zr-J 591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer (2015) (3)
Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. (2020) (3)
Expression of ID Genes in Differentiated Elements of Human Male Germ Cell Tumors (2001) (3)
566 EVALUATION OF LYMPH NODE COUNTS IN PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION (2010) (3)
Adrenal Pathology in the Adult: A Urological Pathologist’s Perspective (2016) (3)
MP24-01 RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN PATIENTS WITH MICROSATELLITE INSTABLE AND HIGH TUMOR MUTATIONAL BURDEN PROSTATE CANCER (2021) (3)
Clinicopathologic and genomic characterization of parenchymal brain metastases (BM) in prostate cancer (PCa). (2019) (3)
Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer. (2022) (3)
Data Set for the Reporting of Carcinoma of the Renal Pelvis and Ureter—Nephroureterectomy and Ureterectomy Specimens (2019) (3)
Untreated hypernephroma of thirty-three years. (1993) (3)
Bladder Biopsy Interpretation (Biopsy Interpretation Series) (2003) (3)
Ultrasonic, Spectrum-Analysis, Tissue-Typing Images for Prostate-Biopsy Guidance and Staging (1997) (2)
Clinical Stage T1c Prostate Cancer: Evaluation with Endorectal MRImagingandMRSpectroscopic (2009) (2)
Abstract 662: Molecular characterisation ofERG,ETV-1andPTEN- gene loci identifies patients at low and high risk of death from prostate cancer (2010) (2)
Evaluation of soluble B7x as a serum marker in patients with clear cell renal cell carcinoma (2008) (2)
Publisher Correction: Integrating digital pathology into clinical practice (2021) (2)
Thoracic Metastasectomy in Germ Cell Tumor Patients Treated with First-Line Versus Salvage. (2020) (2)
1430: Association of Cysteine-Rich Secretory Protein 3 and Beta-Microseminoprotein with Outcome after Radical Prostatectomy: Evaluation with a Tissue Microarray of 947 Primary Prostate Cancers (2007) (2)
CD8+ tumor-infiltrating lymphocytes as a statistically significant marker of disease recurrence and survival in transitional cell carcinoma patients. (2006) (2)
Abstract 2969: Progress in The Cancer Genome Atlas bladder cancer project (2015) (2)
Next-generation sequencing (NGS) of tissue and cell free DNA (cfDNA) to identify somatic and germline alterations in advanced prostate cancer. (2017) (2)
Establishing a neoadjuvant platform for developing targeted agents: Degarelix prior to prostatectomy for patients with intermediate- and high-risk prostate cancer. (2014) (2)
TERT Copy Number Alterations, Promoter Mutations and Rearrangements in Adrenocortical Carcinomas (2021) (2)
MP23-16 TCEB1-MUTATED RENAL CELL CARCINOMA: A DISTINCT GENOMIC AND MORPHOLOGIC SUBTYPE (2014) (2)
Reversal of the low-affinity neurotrophin receptor stromal-epithelial expression pattern between benign and malignant human prostate. (1998) (2)
Phase I trial of exogenous testosterone (T) for the treatment of castrate metastatic prostate cancer (PC). (2004) (2)
Tumor-directed PET imaging of metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled antiprostate-specific membrane antigen (PSMA) antibody J591. (2015) (2)
An Enterprise Approach for Pathology Reporting Utilizing PDFFunctionality for the Electronic Medical Record (2016) (2)
PROGNOSTIC IMPACT OF HISTOLOGICAL SUBTYPE IN PATIENTS WITH SURGICALLY TREATED LOCALIZED RENAL CELL CARCINOMA (2014) (2)
Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series (2022) (2)
A comparison of adult rhabdomyosarcoma and high-grade neuroendocrine carcinoma of the urinary bladder reveals novel PPP1R12A fusions in rhabdomyosarcoma. (2019) (2)
MP35-19 SORBITOL AS A NOVEL MECHANISM OF HYPOXIA-INDUCIBLE FACTOR (HIF) PATHWAY ACTIVATION IN CLEAR CELL PAPILLARY RENAL CELL CARCINOMA (CCPRCC) (2014) (2)
Clinical utility of subclassifying positive surgical margins at radical prostatectomy (2021) (2)
Predictors of post-treatment prostatic biopsy outcome after 3-dimensional conformal radiotherapy for patients with clinically localized prostate cancer (2000) (2)
Genomic characterization of primary and metastatic prostate cancer (PC) using a targeted next-generation sequencing assay. (2015) (2)
Small cell carcinoma of the bladder (SCCB): Clinical, histopathologic, and genomic predictors of clinical outcomes. (2017) (2)
Molecular and Immunohistochemical Markers of Diagnostic and Prognostic Value in Testicular Tumors (2015) (2)
Protocol for malignant and potentially malignant neoplasms of the testis and paratestis. (2000) (2)
Renal Pelvis and Ureter (2017) (2)
MicroRNA as novel blood-based biomarkers in clear cell renal cell carcinoma. (2013) (2)
A phase I/IIa trial of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging with 89Zr-Df-IAB2M in metastatic prostate cancer (PCa). (2016) (2)
Multilocular Cystic Renal Neoplasm of Low Malignant Potential (2020) (2)
Large cell neuroendocrine carcinoma of the urothelial tract (LNEC): The MSKCC experience. (2021) (1)
Morphologic and Immunohistochemical Assessment of CDH1 Loss of Function Alterations in Prostatic Adenocarcinoma. (2019) (1)
Multimodality imaging using proton magnetic resonance spectroscopic imaging and 18F-fluorodeoxyglucose-positron emission tomography in local prostate cancer (2017) (1)
Immunochemistry for p 16 , but not Rb or p 21 , is an independent predictor of prognosis in conservatively treated , clinically localised prostate cancer (2015) (1)
PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) EXPRESSION POST-NEOADJUVANT ANDROGEN DEPRIVATION THERAPY: COMPARISON OF 7311 AND HYBRITECH PM2J004.5 IN PARAFFIN EMBEDDED PROSTATE TISSUE (1999) (1)
Changing demographics and the contemporary surgical management of renal cortical tumors (2004) (1)
Editorial comment. Tumor grade at margins of resection in radical prostatectomy specimens is an independent predictor of prognosis. (2010) (1)
PD15-01 CHARACTERIZING THE DOMINANT/INDEX LESION IN PROSTATE CANCER: IMPLICATIONS FOR GRADING AND STAGING (2014) (1)
Loss of avidin-binding activity in renal cell carcinoma (1990) (1)
Comparison of genomic alterations in bladder urothelial tumors with and without telomerase reverse transcriptase promoter mutation using a next-generation sequencing assay. (2017) (1)
Dataset for reporting of carcinoma of the urethra (in urethrectomy specimens): recommendations from the International Collaboration on Cancer Reporting (ICCR) (2019) (1)
Protocol for Malignant and Potentially Malignant Neoplasms of the Testis and Paratestis (2000) (1)
Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT). (2019) (1)
Abstract 2808: Characterization of KRAS rearrangements in metastatic prostate cancer (2011) (1)
Correction to: Novel, emerging and provisional renal entities: the Genitourinary Pathology Society (GUPS) update on renal neoplasia (2021) (1)
Pathology of bladder cancer: assessment of the primary lesion and response to therapy. (1990) (1)
Spatiotemporal evolution of the ccRCC microenvironment links intra-tumoral heterogeneity to immune escape (2022) (1)
Intratumoral heterogeneity of ERBB2/HER2 expression in micropapillary urothelial carcinoma. (2017) (1)
Absence of structural alterations of the multidrug resistance genes in transitional cell carcinoma (2004) (1)
MP73-17 SINGLE-INSTITUTIONAL ANALYSIS OF PATIENTS WITH CLEAR-CELL PAPILLARY RENAL CELL CARCINOMA (2016) (1)
Renal tumor in a 62-year-old male. (1988) (1)
An update on computational pathology tools for genitourinary pathology practice: A review paper from the Genitourinary Pathology Society (GUPS) (2022) (1)
Case report 576. Anaplastic sacrococcygeal chordoma (dedifferentiated chordoma). (1989) (1)
Ki-67 is an independent predictor of outcome in conservatively treated clinically localised prostate cancer (2008) (1)
PATHOLOGY INFORMATICS SUMMIT 2018 (2018) (1)
FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation (2022) (1)
Oncologic Outcomes of Total Length Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer (2022) (1)
Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy. (2022) (1)
Urethra (2020) (1)
Renin Production by Juxtaglomerular Cell Tumors and Clear Cell Renal Cell Carcinoma and the Role of Angiotensin Signaling Inhibitors. (2022) (1)
Genomic comparison of matched primary and metastatic germ cell tumors (GCT). (2017) (1)
Adult Wilms Tumor (2022) (1)
818: Protein Expression Profiles for JAG-1 and NFK-B Suggest Converging Roles in Prostate Cancer Progression (2006) (1)
Changing demographics and the contemporary surgical management of renal cortical tumors. (2004) (1)
Immunohistochemical Expression of Renin & GATA3 Help Distinguish Juxtaglomerular Cell Tumors from Renal Glomus Tumors. (2022) (1)
A Phase I/II Study for Analytic Validation of Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer (2015) (1)
Long-term survival rates after chemotherapy (CTx) in patients (pts) with nonseminomatous (NS) germ cell tumors (GCT) with teratoma (T). (2013) (1)
Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype. (2022) (1)
Review Article Molecular genetics of testicular germ cell tumors (2012) (1)
Practice Patterns in Reporting Tertiary Grades at Radical Prostatectomy: Survey of a Large Group of Experienced Urologic Pathologists. (2019) (1)
847: Prospective Evaluation of P53 as a Prognostic Marker in T1 Transitional Cell Carcinoma (TCC) of the Bladder (2006) (1)
CLINICAL UROLOGY: Letters to the EditorRE: HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED CANCER (2001) (1)
1005: Clinical and Pathologic Characteristics of Anterior Prostate Cancers (2005) (1)
An exploratory study of endorectal MRI and spectroscopy of the prostate as pre-operative predictive biomarkers of biochemical relapse after radical prostatectomy (2011) (1)
Expression of Class I and Class II Major Histocompatibility Complex (MHC) Antigens in Renal Cell Carcinoma (RCC) (1987) (0)
1139: Risk Adjusted Analysis of Positive Surgical Margins Following Laparoscopic and Retropubic Radical Prostatectomy (2006) (0)
MP16-06 QUANTIFICATION OF SECONDARY GLEASON PATTERN 4 IN PATIENTS WITH GLEASON SCORE 3+4=7/GRADE GROUP 2 ON BIOPSY AND RISK OF ADVERSE PATHOLOGY AT RADICAL PROSTATECTOMY (2018) (0)
EVALUATION OF CANCER CONTROL AFTER OPEN AND LAPAROSCOPIC RADICAL PROSTATECTOMY: 10-YEAR EXPERIENCE (2009) (0)
471: Biopsy Gleason 8-10 Prostate Cancer: Incidence of Downgrading and Outcome (2005) (0)
192 HIGH GRADE TUMOR VOLUME IS A POWERFUL MARKER IN PREDICTING BIOCHEMICAL RECURRENCE FOLLOWING RADICAL PROSTATECTOMY FOR LOCALIZED PROSTATE CANCER (2012) (0)
Comprar Biopsy Interpretation Of The Bladder 3rd Ed. | Jonathan I. Epstein | 9781496315045 | Lippincott Williams & Wilkins (2016) (0)
Clinical features and outcomes of secondary somatic malignancy (SSM) associated with primary mediastinal nonseminomatous germ cell tumors (PM-NSGCT). (2019) (0)
PD47-01 GENOMIC DETERMINANTS OF NESTED VARIANT UROTHELIAL CARCINOMA (2020) (0)
285: The Impact of Socioeconomic Factors on Prostate Cancer Outcomes in a Large Series of African-American Patients (2007) (0)
202 MTOR PATHWAY IN PAPILLARY RENAL CELL CARCINOMA (PAPRCC): PROGNOSTIC ROLE AND POTENTIAL TARGET OF THERAPY (2010) (0)
Urologic Pathology: Poster#320 MOLECULAR, IMMUNOHISTOCHEMICAL AND MORPHOLOGIC ANALYSIS OF UROTHELIAL CARCINOMA WITH ERBB2/ERBB3 MUTATIONS (2014) (0)
Genomic determinants of nested variant urothelial carcinoma. (2020) (0)
Using Departments of Pathology And (2011) (0)
943 ARE RESULTS OF FOCAL THERAPY FOR LOCALIZED PROSTATE CANCER ONLY DUE TO TUMOUR ABLATION? CRITICAL ANALYSIS OF DEFINITIONS FOR SUCCESS APPLIED IN A COHORT OF ACTIVE SURVEILLANCE PATIENTS (2010) (0)
1068 ADVERSE OUTCOMES IN CLEAR CELL RENAL CELL CARCINOMA WITH MUTATIONS OF EPIGENETIC REGULATORS BAP1 AND SETD2 (2013) (0)
971 A COMPREHENSIVE REVIEW OF THE CLINICAL PRESENTATION, PATHOLOGIC FINDINGS, AND OUTCOMES IN REGRESSED TESTICULAR GERM CELL TUMORS (2011) (0)
COMPARISON OF GENOMIC ALTERATIONS IN BLADDER UROTHELIAL TUMORS WITH AND WITHOUT TELOMERASE REVERSE TRANSCRIPTASE PROMOTER MUTATION USING A NEXT‐GENERATION SEQUENCING ASSAY: MP65‐15 (2017) (0)
Single-institutional analysis of patients with clear-cell papillary renal cell carcinoma. (2016) (0)
Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape (2022) (0)
Preface to the fifth edition (2010) (0)
Long-term follow-up of bilateral sporadic renal tumors1 (2004) (0)
Reply by Authors. (2020) (0)
MP16-15 COMPREHENSIVE ANALYSIS OF ONCOGENIC EVENTS IN TRANSLOCATION RENAL CELL CARCINOMA (2019) (0)
407 THE RELATIONSHIP BETWEEN THE LINEAR EXTENT OF POSITIVE SURGICAL MARGIN OR INTIMATE CAPSULAR CONTACT IN PROSTATECTOMY SPECIMENS AND PROGRESSION (2010) (0)
Genomic categorization of high-grade unclassified renal cell carcinoma to refine prognostication and therapeutic approach (2019) (0)
Pathology of the Testis and its Adnexa (1987) (0)
Association of preoperative neutrophil-to-lymphocyte ratio with immune populations in the tumor microenvironment of patients with clear cell renal cell carcinoma. (2018) (0)
Comprehensive investigation of the molecular underpinnings of translocation renal cell carcinoma (2019) (0)
Correlation between pretreatment MRI/MRSI data and tissue molecular marker levels for characterization of prostate cancer and prediction of disease recurrence (2009) (0)
788: Microarray-Based Nomogram for Disease Recurrence After Radical Prostatectomy: Combining Gene Expression Information with Clinical Variables to Enhance Predictive Accuracy (2004) (0)
NUO 2902 Spectrum analysis for classifying and evaluating prostate tissue (1997) (0)
469 GLOBAL METABOLIC PROFILING OF CLEAR CELL RENAL CELL CARCINOMA (2013) (0)
Genitourinary Pathology (2016) (0)
MP18-06 CLINICOPATHOLOGIC IMPLICATIONS OF ATYPICAL SMALL ACINAR PROLIFERATION (ASAP) IN THE ERA OF ACTIVE SURVEILLANCE (2019) (0)
Modulation of blood group antigens in human urothelial carcinoma (1988) (0)
Global metabolic profiling of clear cell renal cell carcinoma. (2013) (0)
Correlations Allelic Deletions in Renal Tumors : Histopathological Updated (2007) (0)
Helicobacter pylori and Gastroduodenal Secretory Function (1996) (0)
MP23-09 INTEGRATED ANALYSIS OF METASTATIC DISEASE IN CLEAR CELL RENAL CELL CARCINOMA: A COLLABORATIVE TCGA ANALYSIS (2014) (0)
Resource Integrative Clinical Genomics of Advanced Prostate Cancer (2016) (0)
Metabolic signature of prostate cancer as detected with proton magnetic resonance spectroscopic imaging and 18 F-fluorodeoxyglucose-positron emission tomography (2012) (0)
Preface to the Sixth Edition (2015) (0)
Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT). (2018) (0)
Correction: Integrating digital pathology into clinical practice (2021) (0)
Urological Survey Urological Oncology: Renal, Ureteral and Retroperitoneal Tumors Re: Immunoexpression Status and Prognostic Value of mTOR and Hypoxia-Induced Pathway Members in Primary and Metastatic Clear Cell Renal Cell Carcinomas (2011) (0)
Phase II Trial of Suramin in Patients with Advanced Renal Cell Carcinoma : Treatment Results , Pharmacokinetics , and Tumor Growth Factor Expression 1 (2006) (0)
DICER1-Associated Anaplastic Sarcoma of the Kidney With Coexisting Activating PDGFRA D842V Mutations and Response to Targeted Kinase Inhibitors in One Patient. (2022) (0)
PROGNOSTIC FACTORS FOR RELAPSE IN PATIENTS WITH LOW VOLUME (pN1) NON-SEMINOMATOUS GERM CELL TUMOR (NSGCT) FOLLOWING PRIMARY RETROPERITONEAL LYMPHADENECTOMY (RPLND) (1999) (0)
Anatomy of the Urinary Bladder Revisited: Implications for Diagnosis and Staging of Bladder Cancer (2015) (0)
Abstract 3515: Pathway convergent evolution underscores treatment response to MTOR inhibitors in kidney cancers. (2013) (0)
CLASSIFICATION OF TESTICULAR GERM CELL TUMORS : INSIGHTS FROM IMMUNOHISTOCHEMISTRY (2008) (0)
The Predictive Power of Prostate Cancer Extent Measurements in a Large Watchful Waiting Cohort (2009) (0)
Understanding the genomic underpinnings of metastatic chromophobe renal cell carcinoma. (2016) (0)
FOLLICULAR THYROID NEOPLASMS. AUTHORS' REPLY (1991) (0)
Cell Reports Resource The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (2018) (0)
Erratum to: Prospective evaluation of plasma kinetic bipolar resection of bladder cancer: comparison to monopolar resection and pathologic findings (2014) (0)
637: Clinical Significance of Prostate Cancers Detected by Extended Biopsy (2004) (0)
Clinical and immunogenomic outcomes of consolidative cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint blockade. (2023) (0)
Author response: Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma (2019) (0)
Prostate Biopsy Interpretation (1996) (0)
Chromophobe renal cell carcinoma: results from a large single-institutional series (2019) (0)
MP47-14 MUTATION ANALYSIS OF AGGRESSIVE CHROMOPHOBE RENAL CELL CANCER PATIENTS (2015) (0)
Pathologic correlation of 89Zr-Df-IAB2M antiprostate-specific membrane antigen (PSMA) minibody in patients with metastatic prostate cancer. (2015) (0)
MP44-07 A CRITICAL ANALYSIS AND VALIDATION OF THE RENAL CELL CARCINOMA BIOMARKER LITERATURE USING THE CANCER GENOME ATLAS (TCGA) (2015) (0)
Estimation of 12p Copy Number in Paraffin-Embedded Tissue Sections of Germ Cell Tumours by In Situ Hybridization of a Microdissected 12p Probe (1994) (0)
Abstract LB-070: Next generation sequencing of prostate cancer reveals germline and somatic alterations detected at diagnosis and at metastasis that may impact clinical decision making (2016) (0)
Integrated analysis of metastatic disease in clear cell renal cell carcinoma: A collaborative TCGA analysis. (2014) (0)
CLEAR CELL HISTOLOGY REPRESENTS WORSE PROGNOSIS IN PATIENTS UNDERGOING SURGICAL TREATMENT FOR RENAL CELL CARCINOMA (2009) (0)
Impact of Zone of Origin in Anterior Dominant Prostate Cancer: Long-Term Biochemical Recurrence-Free Survival in an Anatomically Well-Characterized Cohort. (2022) (0)
PD39-10 LONG-TERM SURVIVORS WITH SARCOMATOID RENAL CELL CARCINOMA (2020) (0)
Everolimus (E) plus bevacizumab (B) is effective first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) with papillary features (PF): Results from a phase II trial. (2018) (0)
657 RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED, HIGH RISK PROSTATE CANCER: IMPACT OF THE DEFINITION AND SURGICAL APPROACH ON OUTCOME (2010) (0)
Personalized Medicine and Imaging Presence of Somatic Mutations within PIK 3 CA , AKT , RAS , and FGFR 3 but not BRAF in Cisplatin-Resistant Germ Cell Tumors (2014) (0)
677 RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED, HIGH RISK PROSTATE CANCER: IMPACT OF THE DEFINITION AND SURGICAL APPROACH ON OUTCOME (2010) (0)
Abstract 128: Comprehensive molecular characterization of 412 muscle-invasive urothelial bladder carcinomas: final analysis of The Cancer Genome Atlas (TCGA) project (2016) (0)
Clinical features and outcomes of secondary somatic malignancy (SSM) arising from teratoma in late relapse germ cell tumor (GCT). (2019) (0)
A study of endorectal MRI and MRSI of the prostate as predictive biomarkers of biochemical relapse after radical prostatectomy (2010) (0)
Reply: To PMID 24094653. (2013) (0)
611 MICRORNA AS NOVEL BLOOD-BASED BIOMARKERS IN CLEAR CELL RENAL CELL CARCINOMA (2013) (0)
UPDATE ON THE 4TH EDITION OF THE WORLD HEALTH ORGANIZATION CLASSIFICATION OF UROTHELIAL TUMOURS* (2016) (0)
Non-Muscle-Invasive Low- and High-Grade Neoplasia (2012) (0)
Editor's Note: Activator Protein-1 Transcription Factors Are Associated with Progression and Recurrence of Prostate Cancer. (2023) (0)
MP7-13 GENETIC SIGNATURES ARE ASSOCIATED WITH ADVERSE PATHOLOGIC AND CLINICAL OUTCOMES IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA (UTUC) (2015) (0)
Genomic and metabolic characterization of succinate dehydrogenase B deficient renal cell carcinoma. (2016) (0)
Spontaneous Dissecting Subclavian Aneurysm — A Case Report (1983) (0)
Author Correction: FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation (2022) (0)
1149: Impact of a Multidisciplinary Continuous Quality Improvement Program on the Positive Surgical Margin Rate after Laparoscopic Radical Prostatectomy (2006) (0)
Resection of primary nonseminomatous germ cell tumors of the anterior mediastinum: A 28-year experience at Memorial Sloan-Kettering Cancer Center (2009) (0)
1774: Predicting Disease Specific Survival at the Time of Diagnosis Utilizing Clinical Variables Integrated with Quantitative Immunofluorescence (2007) (0)
MORPHOLOGIC CHARACTERISTICS AT THE TIME OF PROSTATECTOMY IN LYMPH NODE POSITIVE PATIENTS (2009) (0)
715 Can transrectal needle biopsy be optimized to detect nearly all prostate cancer with volume ≥0.5 cc? A three-dimensional analysis (2013) (0)
1057 THE IMPACT OF PROSTATE CANCER NATURAL HISTORY ON FOCAL ABLATION RESULTS (2010) (0)
Memorial Sloan-Kettering Cancer Center The 20th Annual Course on the Surgical Pathology of Neoplastic Diseases (1997) (0)
639 EVALUATION OF CANCER CONTROL AFTER OPEN AND LAPAROSCOPIC RADICAL PROSTATECTOMY (2009) (0)
Histologic determinants of long-term overall survival in patients (pts) with germ cell tumors (GCT). (2017) (0)
911 PREDICTION OF OUTCOME AFTER RADICAL PROSTATECTOMY USING A TISSUE MICROARRAY OF 947 PRIMARY PROSTATE CANCERS AND IMMUNOHISTOCHEMICAL DETECTION OF CYSTEINE-RICH SECRETORY PROTEIN 3 (CRISP-3) AND BETA-MICROSEMINOPROTEIN (MSP) (2007) (0)
201 HIF 1 ALPHA AND PHOS S6 ARE INDEPENDENT PREDICTORS OF SURVIVAL IN CLEAR CELL RENAL CELL CARCINOMA (CCRCC) (2010) (0)
BOOK REVIEWS Sternberg’s Diagnostic Surgical Pathology, 4th ed (2005) (0)
Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer (2020) (0)
Reply from Authors re: James W.F. Catto, Shahrokh F. Shariat. The Changing Face of Renal Cell Carcinoma: The Impact of Systematic Genetic Sequencing on Our Understanding of This Tumor's Biology. Eur Urol 2013;63:855–7 (2013) (0)
CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract. (2021) (0)
IMMUNOHISTOCHEMICAL COMPARISON OF FIVE ANTIBODIES TO PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) IN BENIGN TISSUES (1999) (0)
Comment: Duplication of the Fusion of TMPRSS2 to ERG Sequences Identifies Fatal Human Prostate Cancer (2008) (0)
Efficient Visualization of Whole Slide Images in Web-based Viewers for Digital Pathology. (2021) (0)
MP28-08 CLINICOPATHOLOGIC AND GENOMIC EVALUATION OF TRANSLOCATION RENAL CELL CARCINOMA (2018) (0)
The 2014 Fred W. Stewart Award: Thomas M. Ulbright, MD. (2016) (0)
Regarding the Focal Treatment of Prostate Cancer: Inference of the Gleason Grade From MR Spectroscopic Imaging (2007) (0)
MP42-14 SARCOMATOID FEATURES IN RENAL CELL CARCINOMA: RETHINKING THE STAGE-SURVIVAL PARADIGM (2019) (0)
Androgen Receptor in Tumor and Stroma in Conservatively Treated Prostate Cancer (2012) (0)
Cancer Immunity 3:19 (2003)-ARTICLE (2003) (0)
Molecular stratification of high-grade unclassified renal cell carcinoma to improve prognostication and management strategy. (2019) (0)
NUTM1‐fusion positive malignant neoplasms of the genitourinary tract: A report of six cases highlighting involvement of unusual anatomic locations and histologic heterogeneity (2022) (0)
Urological Survey Infection and Inflammation of Genitourinary Tract Re : Timing of Surgical Antibiotic Prophylaxis and the Risk of Surgical Site Infection (2013) (0)
Abstract 987: Comprehensive characterization of urothelial bladder cancer: a TCGA Project update (2014) (0)
PD56-06 CLINICAL FEATURES AND OUTCOMES OF SECONDARY SOMATIC MALIGNANCY ARISING FROM TERATOMA IN LATE RELAPSE GERM CELL TUMOR (2019) (0)
Somatic ERCC2 Mutations Confer Cisplatin Sensitivity in Muscle-Invasive Urothelial Cancer (2014) (0)
673: Utility of Resection of Additional Peri-Prostatic Tissue in Patients Undergoing Radical Prostatectomy (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Victor E. Reuter?

Victor E. Reuter is affiliated with the following schools:

Victor E. Reuter's Academic­Influence.com Rankings

Why Is Victor E. Reuter Influential?

Victor E. Reuter's Published Works

Published Works

What Schools Are Affiliated With Victor E. Reuter?

Victor E. Reuter's AcademicInfluence.com Rankings